{"id":"tj202-lenalidomide-and-dexamethasone","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL848","moleculeType":"Small molecule","molecularWeight":"259.26"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lenalidomide works by binding to cereblon, a protein that regulates the activity of other proteins involved in the immune response. This binding leads to the degradation of certain proteins that promote the growth and survival of cancer cells. Dexamethasone, on the other hand, has a broad range of effects on the immune system, including the suppression of inflammation and the modulation of immune cell activity.","oneSentence":"Lenalidomide is an immunomodulatory drug that stimulates the immune system to attack cancer cells, while dexamethasone is a corticosteroid that has anti-inflammatory and immunosuppressive properties.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:59.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT03952091","phase":"PHASE3","title":"TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"TJ Biopharma Co., Ltd.","startDate":"2019-03-27","conditions":"Multiple Myeloma in Relapse, Refractory Multiple Myeloma","enrollment":289}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TJ202, Lenalidomide and Dexamethasone","genericName":"TJ202, Lenalidomide and Dexamethasone","companyName":"TJ Biopharma Co., Ltd.","companyId":"tj-biopharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TJ202, Lenalidomide, and Dexamethasone are being compared to Lenalidomide and Dexamethasone in a Phase 3 study for the treatment of relapsed or refractory multiple myeloma. The study is being conducted by TJ Biopharma Co., Ltd. to evaluate the efficacy of TJ202 in combination with Lenalidomide and Dexamethasone.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}